In COAD, FGL2 can be used as a new prognostic marker and an effective therapeutic target, and the overexpression of FGL2 enhances cancer cell invasion, induces epithelial mesenchymal transition (EMT), and promotes COAD invasion and metastasis (50). Here, FGL2 is linked to cancer.